Your browser doesn't support javascript.
loading
Drug screening of food and drug administration-approved compounds against Babesia bovis in vitro.
Li, Yongchang; Liu, Mingming; Rizk, Mohamed Abdo; Moumouni, Paul Franck Adjou; Lee, Seung-Hun; Galon, Eloiza May; Guo, Huanping; Gao, Yang; Li, Jixu; Beshbishy, Amani Magdy; Nugraha, Arifin Budiman; Ji, Shengwei; Tumwebaze, Maria Agnes; Benedicto, Byamukama; Yokoyama, Naoaki; Igarashi, Ikuo; Xuan, Xuenan.
Afiliación
  • Li Y; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Liu M; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Rizk MA; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan; Department of Internal Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Mansoura University, 35516, Egypt.
  • Moumouni PFA; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Lee SH; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan; College of Veterinary Medicine, Chungbuk National University, Cheongju, 28644, South Korea.
  • Galon EM; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Guo H; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Gao Y; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Li J; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Beshbishy AM; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Nugraha AB; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan; Faculty of Veterinary Medicine, Bogor Agricultural University, Jl. Agatis Kampus IPB Dramaga, Bogor, 16680, Indonesia.
  • Ji S; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Tumwebaze MA; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Benedicto B; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Yokoyama N; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Igarashi I; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan.
  • Xuan X; National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, 080-8555, Hokkaido, Japan. Electronic address: gen@obihiro.ac.jp.
Exp Parasitol ; 210: 107831, 2020 Mar.
Article en En | MEDLINE | ID: mdl-31926147
Babesia (B.) bovis is one of the main etiological agents of bovine babesiosis, causes serious economic losses to the cattle industry. Control of bovine babesiosis has been hindered by the limited treatment selection for B. bovis, thus, new options are urgently needed. We explored the drug library and unbiasedly screened 640 food and drug administration (FDA) approved drug compounds for their inhibitory activities against B. bovis in vitro. The initial screening identified 13 potentially effective compounds. Four potent compounds, namely mycophenolic acid (MPA), pentamidine (PTD), doxorubicin hydrochloride (DBH) and vorinostat (SAHA) exhibited the lowest IC50 and then selected for further evaluation of their in vitro efficacies using viability, combination inhibitory and cytotoxicity assays. The half-maximal inhibitory concentration (IC50) values of MPA, PTD, DBH, SAHA were 11.38 ± 1.66, 13.12 ± 4.29, 1.79 ± 0.15 and 45.18 ± 7.37 µM, respectively. Of note, DBH exhibited IC50 lower than that calculated for the commonly used antibabesial drug, diminazene aceturate (DA). The viability result revealed the ability of MPA, PTD, DBH, SAHA to prevent the regrowth of treated parasite at 4 × and 2 × of IC50. Antagonistic interactions against B. bovis were observed after treatment with either MPA, PTD, DBH or SAHA in combination with DA. Our findings indicate the richness of FDA approved compounds by novel potent antibabesial candidates and the identified potent compounds especially DBH might be used for the treatment of animal babesiosis caused by B. bovis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Babesia bovis / Antiprotozoarios Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Animals Idioma: En Revista: Exp Parasitol Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Babesia bovis / Antiprotozoarios Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Animals Idioma: En Revista: Exp Parasitol Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos